Zomedica Pharma (ZOM) has released an update.
Zomedica Corp. has announced a record-breaking revenue of $7.3 million for the fourth quarter of 2023 and an impressive annual growth of 33%, reaching a full-year revenue of $25.2 million. This growth is attributed to strong performance in both its Diagnostics and Therapeutic Devices segments, along with innovative product launches and strategic acquisitions. The company’s robust financial position is further highlighted by a 69% gross margin and a significant liquidity reserve of $100.5 million.
For further insights into ZOM stock, check out TipRanks’ Stock Analysis page.
